Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis. Doriana Landi , Francesca Bovis , Alfonso Grimaldi , Pietro Osvaldo Annovazzi , Antonio Bertolotto , Alessia Bianchi , Giovanna Borriello , Vincenzo Brescia Morra , Sebastiano Bucello , Maria Chiara Buscarinu , Francesca Caleri , Marco Capobianco , Ruggero Capra , Maria Cellerino , Diego Centonze , Raffaella Cerqua , Clara Grazia Chisari , Marinella Clerico , Eleonora Cocco , Gaia Cola , Cinzia Cordioli , Erica Curti , Alessandro d'Ambrosio , Emanuele D'Amico , Giovanna De Luca , Massimiliano Di Filippo , Sonia Di Lemme , Roberta Fantozzi , Diana Ferraro , Elisabetta Ferraro , Antonio Gallo , Claudio Gasperini , Franco Granella , Matilde Inglese , Roberta Lanzillo , Lorena Lorefice , Giacomo Lus , Simona Malucchi , Monica Margoni , Giorgia Mataluni , Massimiliano Mirabella , Lucia Moiola , Carolina Gabri Nicoletti , Viviana Nociti , Francesco Patti , Federica Pinardi , Emilio Portaccio , Carlo Pozzilli , Paolo Ragonese , Sarah Rasia , Giuseppe Salemi , Elisabetta Signoriello , Francesca Vitetta , Rocco Totaro , Maria Pia Sormani , Maria Pia Amato , Girolama Alessandra Marfia Journal of neurology, neurosurgery, and psychiatry（2022）
摘要
Our findings indicate that in women with MS treated with NTZ before conception, continuation of NTZ throughout pregnancy and its early resumption after delivery mitigate the risk of clinical and radiological reactivation. This approach has no major impact on newborns' outcomes.
更多 查看译文
关键词
MRI, multiple sclerosis, obstetrics
AI 理解论文
溯源树
样例
